CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The LIGHTHER project develops a novel therapy for lung cancer that utilizes light-activated immune responses. It involves loading patient-derived dendritic cells with cancer-targeting peptides, aiming to enhance treatment efficacy and safety through innovative photopharmacology techniques.
Project LIGHTHER (LIGHt-boosted THERapy) focuses on basic studies and early preclinical development of a groundbreaking therapy for one of the deadliest human diseases - lung cancer.
The therapy includes in-patient activation of the immune system by light-controllable cytotoxic peptides, ex vivo loading of the patient’s dendritic cells (DCs) with exosomes or cancer cell lysates obtained using the same peptides, and treatment of the patients with the loaded DCs.
Optimisation of efficacy and safet…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Ukraine, KYIV
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, Karlsruhe
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, Karlsruhe
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
